Virtus Investment Advisers, Inc. Denali Therapeutics Inc. Transaction History
Virtus Investment Advisers, Inc.
- $286 Million
- Q2 2025
A detailed history of Virtus Investment Advisers, Inc. transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Virtus Investment Advisers, Inc. holds 6,300 shares of DNLI stock, worth $108,675. This represents 0.03% of its overall portfolio holdings.
Number of Shares
6,300
Previous 6,991
9.88%
Holding current value
$108,675
Previous $95,000
7.37%
% of portfolio
0.03%
Previous 0.03%
Shares
2 transactions
Others Institutions Holding DNLI
# of Institutions
250Shares Held
135MCall Options Held
148KPut Options Held
15.4K-
Black Rock Inc. New York, NY13.2MShares$227 Million0.01% of portfolio
-
Baillie Gifford & CO12MShares$206 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$204 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.58MShares$114 Million0.01% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL6.26MShares$108 Million0.02% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $2.31B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...